A 20-person Johns Hopkins pilot study found supervised psilocybin doses were associated with reduced symptoms of post-treatment Lyme disease, but the uncontrolled findings need confirmation.

Participants received 15 mg and 25 mg doses two weeks apart, with a reported 52% reduction in overall symptom burden two weeks after the second dose and symptoms remaining 40% to 50% below baseline after six months. The study had no placebo group and could not establish that psilocybin caused the improvements.